Sucampo forms holding company to improve efficiency
This article was originally published in Scrip
Executive Summary
Sucampo Pharmaceuticals is to set itself up with a holding company to provide a more efficient corporate structure. After the changes, Sucampo Pharmaceuticals Inc will be the public company, with three wholly owned subsidiaries: Sucampo Pharma Ltd based in Tokyo and Osaka; Sucampo Pharma Americas Inc, based in Bethesda; andSucampo Pharma Europe, based in Oxford, UK, and Basel, Switzerland. Dr Sachiko Kuno, a co-founder of the company and a former CEO, will rejoin the board on completion of the changes. The company will also undertake a stock buyback of up to $10 million, and has promoted its acting chief financial officer, Jan Smilek, to CFO.
You may also be interested in...
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.
Theravance's Gut-Selective JAK Inhibitor Disappoints In Ulcerative Colitis Study
Top-line results from a Phase IIb study of Theravance’s potential gut-selective JAK inhibitor izencitinib have not matched expectations, and results from a similar early-stage study in Crohn’s disease with the Janssen-partnered candidate are now awaited at the end of the year or in early 2022.